Published in Blood Weekly, March 24th, 1997
Martijn Groenink, Netherlands Red Cross Blood Transfusion Service, Amsterdam, Netherlands, and colleagues previously reported on the antiviral capacity of HSA that was modified by the introduction of a single (Suc-HSA) or two carboxylic groups (Aco-HSA) per lysine residue, yielding strongly negatively charged polypeptides. More recently, they reported the antiviral effect of the modified HSAs on replication of primary HIV-1 isolates that differed with respect to synctium-inducing (SI) capacity and cell tropism ("Potent Inhibition of Replication of Primary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.